应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
TVRD Tvardi Therapeutics Inc
未开盘 07-31 16:00:00 EDT
25.96
+0.27
+1.05%
盘后
25.96
+0.00
0.00%
16:10 EDT
最高
26.55
最低
25.61
成交量
3.19万
今开
26.00
昨收
25.69
日振幅
3.69%
总市值
2.43亿
流通市值
2.06亿
总股本
935.55万
成交额
82.91万
换手率
0.40%
流通股本
792.78万
市净率
-2.41
ROE
--
每股收益
-5.43
52周最高
34.31
52周最低
8.13
市盈率
-4.78
股息
0.00
股息收益率
0.00
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Tvardi Therapeutics(TVRD.US)获奥本海默首次覆盖,给予优于大市评级, 目标价65.00美元。
金融界 · 05-21
Tvardi Therapeutics(TVRD.US)获奥本海默首次覆盖,给予优于大市评级, 目标价65.00美元。
加载更多
公司概况
公司名称:
Tvardi Therapeutics Inc
所属市场:
NASDAQ
上市日期:
2014-01-31
主营业务:
Tvardi Therapeutics, Inc.于2017年12月20日注册成立,是一家总部位于德克萨斯州休斯顿的特拉华州公司。该公司是一家临床阶段的生物制药公司,专注于开发针对STAT3的新型口服小分子疗法,以治疗具有重大未满足需求的纤维化驱动疾病。基于其创始人的开创性工作和对转录因子STAT3的深刻理解,该公司设计了一种创新方法来直接抑制STAT3,这是一种经过高度验证但在历史上是不可药物的靶点。利用这些专业知识,该公司正在开发具有差异化作用机制和方便的口服给药的STAT3抑制剂管道。该公司的主要候选产品TTI-101目前处于2期临床开发阶段,用于治疗纤维化驱动的疾病,初步重点是特发性肺纤维化、IPF和肝细胞癌、HCC。
发行价格:
11.00
{"stockData":{"symbol":"TVRD","market":"US","secType":"STK","nameCN":"Tvardi Therapeutics Inc","latestPrice":25.96,"timestamp":1753992000000,"preClose":25.69,"halted":0,"volume":31876,"hourTrading":{"tag":"盘后","latestPrice":25.96,"preClose":25.96,"latestTime":"16:10 EDT","volume":475,"amount":12331,"timestamp":1753992604282},"delay":0,"floatShares":7927832,"shares":9355542,"eps":-5.433655,"marketStatus":"未开盘","change":0.27,"latestTime":"07-31 16:00:00 EDT","open":26,"high":26.5526,"low":25.605,"amount":829109.295456,"amplitude":0.036886,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.433655,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1754035200000},"marketStatusCode":0,"adr":0,"listingDate":1391144400000,"exchange":"NASDAQ","adjPreClose":25.69,"postHourTrading":{"tag":"盘后","latestPrice":25.96,"preClose":25.96,"latestTime":"16:10 EDT","volume":475,"amount":12331,"timestamp":1753992604282},"volumeRatio":1.325593},"requestUrl":"/m/hq/s/TVRD","defaultTab":"news","newsList":[{"id":"2537932987","title":"Tvardi Therapeutics(TVRD.US)获奥本海默首次覆盖,给予优于大市评级, 目标价65.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2537932987","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537932987?lang=zh_cn&edition=full","pubTime":"2025-05-21 23:22","pubTimestamp":1747840948,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics(TVRD.US)获奥本海默首次覆盖,给予优于大市评级, 目标价65.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/21232250576773.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","TVRD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://tvarditherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0487},{"period":"1month","weight":0.172},{"period":"3month","weight":-0.0288},{"period":"6month","weight":0.7879},{"period":"1year","weight":1.0716},{"period":"ytd","weight":0.4139}],"compareEarnings":[{"period":"1week","weight":-0.0037},{"period":"1month","weight":0.0234},{"period":"3month","weight":0.1153},{"period":"6month","weight":0.0503},{"period":"1year","weight":0.1475},{"period":"ytd","weight":0.0785}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Tvardi Therapeutics, Inc.于2017年12月20日注册成立,是一家总部位于德克萨斯州休斯顿的特拉华州公司。该公司是一家临床阶段的生物制药公司,专注于开发针对STAT3的新型口服小分子疗法,以治疗具有重大未满足需求的纤维化驱动疾病。基于其创始人的开创性工作和对转录因子STAT3的深刻理解,该公司设计了一种创新方法来直接抑制STAT3,这是一种经过高度验证但在历史上是不可药物的靶点。利用这些专业知识,该公司正在开发具有差异化作用机制和方便的口服给药的STAT3抑制剂管道。该公司的主要候选产品TTI-101目前处于2期临床开发阶段,用于治疗纤维化驱动的疾病,初步重点是特发性肺纤维化、IPF和肝细胞癌、HCC。","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.042039},{"month":2,"riseRate":0.333333,"avgChangeRate":0.019771},{"month":3,"riseRate":0.583333,"avgChangeRate":0.021822},{"month":4,"riseRate":0.25,"avgChangeRate":-0.048535},{"month":5,"riseRate":0.583333,"avgChangeRate":0.009735},{"month":6,"riseRate":0.583333,"avgChangeRate":-0.017433},{"month":7,"riseRate":0.5,"avgChangeRate":0.091173},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.002014},{"month":9,"riseRate":0.181818,"avgChangeRate":-0.067808},{"month":10,"riseRate":0.545455,"avgChangeRate":-0.031996},{"month":11,"riseRate":0.545455,"avgChangeRate":0.051738},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.02182}],"exchange":"NASDAQ","name":"Tvardi Therapeutics Inc","nameEN":"Tvardi Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tvardi Therapeutics Inc(TVRD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Tvardi Therapeutics Inc(TVRD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Tvardi Therapeutics Inc,TVRD,Tvardi Therapeutics Inc股票,Tvardi Therapeutics Inc股票老虎,Tvardi Therapeutics Inc股票老虎国际,Tvardi Therapeutics Inc行情,Tvardi Therapeutics Inc股票行情,Tvardi Therapeutics Inc股价,Tvardi Therapeutics Inc股市,Tvardi Therapeutics Inc股票价格,Tvardi Therapeutics Inc股票交易,Tvardi Therapeutics Inc股票购买,Tvardi Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tvardi Therapeutics Inc(TVRD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Tvardi Therapeutics Inc(TVRD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}